PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930123
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930123
Measles, Mumps, Rubella (MMR) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of measles, mumps, rubella (MMR) vaccines Market
The global measles, mumps, rubella (MMR) vaccines market is witnessing strong expansion due to rising disease incidence, growing immunization coverage, and sustained government support worldwide. According to Fortune Business Insights, the global MMR vaccines market size was valued at USD 5.17 billion in 2025. The market is projected to grow from USD 5.59 billion in 2026 to USD 14.43 billion by 2034, registering a CAGR of 12.59% during the forecast period. North America dominated the global market with a share of 38.02% in 2025, supported by robust immunization programs and high vaccine uptake.
Measles, mumps, and rubella are highly contagious and potentially life-threatening viral diseases. MMR vaccines are combination vaccines containing live attenuated viruses, administered in two doses-typically at 12 months and again at 4 years of age. The high potency, strong immunogenic response, and long-term protection offered by these vaccines have made them essential components of national immunization schedules across multiple countries.
Market Dynamics
Market Drivers
Rising government initiatives and immunization programs are major drivers of the MMR vaccines market. Countries such as the U.S. and India have incorporated MMR vaccines into their National Immunization Programs (NIP), ensuring free or subsidized access. Support from international organizations such as WHO, UNICEF, and Gavi has significantly expanded vaccine coverage. According to the CDC, as of January 2025, one dose of the MMR vaccine is 93.0% effective against measles, 72% against mumps, and 97% against rubella, reinforcing strong confidence in vaccine effectiveness.
Market Restraints
Vaccine hesitancy remains a key restraint limiting market growth. Factors such as misinformation, religious beliefs, and fear of side effects reduce vaccine acceptance. Reports published in 2023 highlighted parental concerns regarding post-vaccination fever and injection-site pain, which continue to delay immunization in certain populations.
Market Opportunities
Technological advancements, particularly the development of microarray patches (MAPs), offer promising growth opportunities. These needle-free, thermostable delivery systems improve patient compliance and simplify vaccine administration, especially in low- and middle-income countries. UNICEF and WHO have actively supported MAP development, indicating strong future potential.
Market Challenges
Cold chain maintenance remains a critical challenge. MMR vaccines are highly temperature-sensitive, and improper storage or transportation can lead to vaccine wastage and reduced efficacy. Weak cold chain infrastructure in remote regions continues to hinder optimal market expansion.
Market Trends
A key trend shaping the market is the rise in public-private partnerships. Collaboration between governments, NGOs, and pharmaceutical companies is improving vaccine accessibility, strengthening supply chains, and addressing immunization gaps. Increasing measles resurgence globally has further intensified coordinated immunization efforts.
Segmentation Analysis
By Type
The combination vaccine segment dominated the market in 2024 due to convenience, cost-effectiveness, and reduced injection burden. Products such as M-M-R II and PRIORIX support higher patient compliance. The standalone segment maintained a notable share due to disease-specific usage.
By Product
M-M-R II held the largest market share in 2024, driven by decades-long usage and widespread inclusion in national immunization programs. PRIORIX is expected to grow at a strong pace due to U.S. FDA approval and licensing across more than 100 countries.
By Route of Administration
The subcutaneous route dominated the market in 2024, supported by regulatory recommendations and patient comfort. The intramuscular segment also held a significant share due to strong immunogenicity and expanded approvals.
By Age Group
The pediatric segment led the market owing to mandatory childhood vaccination schedules. The adult segment is growing steadily as awareness increases among unvaccinated or partially vaccinated adults.
By Distribution Channel
Government suppliers accounted for the largest share in 2024 due to large-scale procurement for national immunization programs. Hospital and retail pharmacies are expected to grow significantly with expanding vaccination access points.
Regional Outlook
North America generated revenues of USD 1.97 billion in 2025 and USD 2.15 billion in 2026, driven by high vaccination coverage and strong public health infrastructure.
Europe maintained a significant share due to mandatory two-dose schedules across EU/EEA countries.
Asia Pacific is witnessing the fastest growth, supported by large population bases and government-funded vaccination programs, particularly in India.
Latin America and the Middle East & Africa are growing steadily with increasing awareness and improved vaccine access.
Competitive Landscape
The market is led by GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd., supported by strong R&D pipelines and global distribution networks. Other prominent players include Indian Immunologicals Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, and Biological E. Limited.
Conclusion
In conclusion, the global measles, mumps, rubella (MMR) vaccines market is set for robust growth from 2025 to 2034, expanding from USD 5.17 billion in 2025 to USD 14.43 billion by 2034. Strong government initiatives, high vaccine efficacy, and expanding immunization coverage are key growth drivers. However, vaccine hesitancy and cold chain challenges remain critical concerns. Continued innovation, public-private collaboration, and investment in advanced delivery technologies will be essential to sustaining long-term market growth.
Segmentation By Type
- Standalone
- Combination
By Product
- M-M-R II
- PRIORIX
- M-M-RvaxPro
- Tresivac
- Others
By Route of Administration
- Intramuscular
- Subcutaneous
- Others
By Age Group
- Adult
- Pediatric
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Overview: Immunization Coverage, By Key Countries
- 4.4. Technological Advancements in the MMR Vaccines
- 4.5. New Product Launches, By Key Players
- 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships
5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Standalone
- 5.1.2. Combination
- 5.2. Market Analysis, Insights and Forecast - By Product
- 5.2.1. M-M-R II
- 5.2.2. PRIORIX
- 5.2.3. M-M-RvaxPro
- 5.2.4. Tresivac
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Intramuscular
- 5.3.2. Subcutaneous
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Age Group
- 5.4.1. Pediatrics
- 5.4.2. Adults
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital & Retail Pharmacies
- 5.5.2. Government Suppliers
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Standalone
- 6.1.2. Combination
- 6.2. Market Analysis, Insights and Forecast - By Product
- 6.2.1. M-M-R II
- 6.2.2. PRIORIX
- 6.2.3. M-M-RvaxPro
- 6.2.4. Tresivac
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Intramuscular
- 6.3.2. Subcutaneous
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Age Group
- 6.4.1. Pediatrics
- 6.4.2. Adults
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital & Retail Pharmacies
- 6.5.2. Government Suppliers
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Standalone
- 7.1.2. Combination
- 7.2. Market Analysis, Insights and Forecast - By Product
- 7.2.1. M-M-R II
- 7.2.2. PRIORIX
- 7.2.3. M-M-RvaxPro
- 7.2.4. Tresivac
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Intramuscular
- 7.3.2. Subcutaneous
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Age Group
- 7.4.1. Pediatrics
- 7.4.2. Adults
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital & Retail Pharmacies
- 7.5.2. Government Suppliers
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Standalone
- 8.1.2. Combination
- 8.2. Market Analysis, Insights and Forecast - By Product
- 8.2.1. M-M-R II
- 8.2.2. PRIORIX
- 8.2.3. M-M-RvaxPro
- 8.2.4. Tresivac
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Intramuscular
- 8.3.2. Subcutaneous
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Age Group
- 8.4.1. Pediatrics
- 8.4.2. Adults
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital & Retail Pharmacies
- 8.5.2. Government Suppliers
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Standalone
- 9.1.2. Combination
- 9.2. Market Analysis, Insights and Forecast - By Product
- 9.2.1. M-M-R II
- 9.2.2. PRIORIX
- 9.2.3. M-M-RvaxPro
- 9.2.4. Tresivac
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Intramuscular
- 9.3.2. Subcutaneous
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Age Group
- 9.4.1. Pediatrics
- 9.4.2. Adults
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital & Retail Pharmacies
- 9.5.2. Government Suppliers
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Standalone
- 10.1.2. Combination
- 10.2. Market Analysis, Insights and Forecast - By Product
- 10.2.1. M-M-R II
- 10.2.2. PRIORIX
- 10.2.3. M-M-RvaxPro
- 10.2.4. Tresivac
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Intramuscular
- 10.3.2. Subcutaneous
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Age Group
- 10.4.1. Pediatrics
- 10.4.2. Adults
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital & Retail Pharmacies
- 10.5.2. Government Suppliers
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. GSK plc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Serum Institute of India Pvt. Ltd.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Indian Immunologicals Limited
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Zydus Lifesciences Limited
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Takeda Pharmaceutical Company Limited
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. BIOLOGICAL E. LIMITED
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Invivyd, Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Daiichi Sankyo Company, Limited
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. GSK plc.
List of Tables
- Table 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
- Table 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 7: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
- Table 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 13: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 14: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 15: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 16: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
- Table 17: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 18: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 19: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 20: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 21: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 22: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
- Table 23: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 24: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 25: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 26: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 27: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 28: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
- Table 29: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 30: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 31: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 32: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 33: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 34: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
- Table 35: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 36: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025 & 2034
- Figure 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025 & 2034
- Figure 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025 & 2034
- Figure 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 7: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Region, 2025 & 2034
- Figure 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
- Figure 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 13: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
- Figure 14: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
- Figure 15: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
- Figure 16: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 17: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 18: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 19: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country, 2025
- Figure 20: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 21: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
- Figure 22: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 23: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 24: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 25: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
- Figure 26: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
- Figure 27: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
- Figure 28: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 29: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 30: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 33: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
- Figure 34: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 35: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 36: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 37: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
- Figure 38: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
- Figure 39: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
- Figure 40: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 41: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 42: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 45: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
- Figure 46: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 47: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 48: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 49: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
- Figure 50: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
- Figure 51: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
- Figure 52: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 53: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 54: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 57: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
- Figure 58: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 59: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 60: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 61: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
- Figure 62: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
- Figure 63: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
- Figure 64: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 65: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 66: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Measles, Mumps, Rubella (MMR) Vaccines Market Share (%), By Company, 2025
